Opinion|Videos|November 27, 2025
Barriers to Adoption of SC Therapies
Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.
Episodes in this series
Panelists discuss how barriers such as provider hesitancy, reimbursement concerns, and logistical complexities slow the adoption of subcutaneous (SC) therapies. They propose strategies including education, workflow redesign, and advocacy to increase confidence in SC delivery. The discussion emphasizes that as data accumulate and experience grows, institutional and cultural shifts will further integrate SC therapy
Related to this article
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Access and Innovation in North Carolina’s Research Triangle
3
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
4
An Odyssey of Symptoms, Setbacks, Treatments, and a Cure With CAR T-Cell Therapy
5